-transparent.png){kind=logo}
15 patients with myeloproliferative diseases and thrombocythaemia (7 Polycythaemia vera, 5 essential thrombocythaemia, 3 chronic myelogenous leukaemia) were assigned to a therapy with recombinant interferon (recombinant IFN-alpha-2C) in a prospective, controlled trial. Under therapy all patients showed a significant decrease in thrombocyte values. 51% of the patients revealed thrombocyte values within the normal range after 3 months of IFN therapy. Noted side effects of IFN therapy were dose-dependent and clinically well tolerated by the patients.
Related Publications
W Linkesch, and
H Gisslinger, and
H Ludwig, and
R Flener, and
H Sinzinger
January 1985,
Acta medica Austriaca,
W Linkesch, and
H Gisslinger, and
H Ludwig, and
R Flener, and
H Sinzinger
February 1987,
Onkologie,
W Linkesch, and
H Gisslinger, and
H Ludwig, and
R Flener, and
H Sinzinger
October 1987,
Journal of hepatology,
W Linkesch, and
H Gisslinger, and
H Ludwig, and
R Flener, and
H Sinzinger
May 1989,
The American journal of medicine,
W Linkesch, and
H Gisslinger, and
H Ludwig, and
R Flener, and
H Sinzinger
September 1989,
Schweizerische medizinische Wochenschrift,
W Linkesch, and
H Gisslinger, and
H Ludwig, and
R Flener, and
H Sinzinger
October 1992,
British journal of haematology,
W Linkesch, and
H Gisslinger, and
H Ludwig, and
R Flener, and
H Sinzinger
October 2023,
The Journal of pharmacology and experimental therapeutics,
W Linkesch, and
H Gisslinger, and
H Ludwig, and
R Flener, and
H Sinzinger
January 1992,
International journal of STD & AIDS,
W Linkesch, and
H Gisslinger, and
H Ludwig, and
R Flener, and
H Sinzinger
February 1989,
Contact dermatitis,
W Linkesch, and
H Gisslinger, and
H Ludwig, and
R Flener, and
H Sinzinger
January 2019,
Vnitrni lekarstvi,
